Jaguar Health Stock Price

0.0211 (7.13%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Jaguar Health Inc JAGX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0211 7.13% 0.317 19:59:25
Close Price Low Price High Price Open Price Previous Close
0.3117 0.30 0.336 0.30 0.2959
Bid Price Ask Price Spread News
0.317 0.3224 0.0054 1 -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
5,827 7,642,212 $ 0.3106368 $ 2,373,952 5,925,139 0.2852 - 1.47
Last Trade Time Type Quantity Stock Price Currency
19:59:34 formt 23,555 $ 0.317 USD

Jaguar Health Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 13.99M 44.14M 43.91M $ 5.78M $ - -29.59 0.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Jaguar Health News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical JAGX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.3610.37910.28520.32048561,862,454-0.044-12.19%
1 Month0.3820.55950.28520.37172925,228,326-0.065-17.02%
3 Months0.4840.84890.28520.56030315,921,292-0.167-34.5%
6 Months0.50410.84890.28520.53999393,950,314-0.1871-37.12%
1 Year1.321.470.28520.5809312,332,093-1.00-75.98%
3 Years29.078224.000.285215.833,127,863-28.76-98.91%
5 Years252.00324.100.285219.702,019,481-251.68-99.87%

Jaguar Health Description

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products. The company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the marketplace from plants used traditionally in rainforest areas. It operates into two business segments namely Human health and animal health. Its Mytesi (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Your Recent History
Jaguar Hea..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.